EntryPoint Capital LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• EntryPoint Capital LLC has acquired a new stake in Catalyst Pharmaceuticals, purchasing 12,115 shares valued at approximately $294,000 in the first quarter.
• Several other institutional investors also increased their stakes in Catalyst Pharmaceuticals, with 79.22% of the stock now owned by hedge funds and institutional investors.
• Recent analyst ratings indicate a mix of sentiment, with Zacks and Wall Street Zen downgrading their ratings to a "hold", while Cantor Fitzgerald upgraded to a "strong-buy".

EntryPoint Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 12,115 shares of the biopharmaceutical company's stock, valued at approximately $294,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of CPRX. Park Square Financial Group LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $29,000. Sound Income Strategies LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the first quarter worth about $64,000. GAMMA Investing LLC grew its holdings in shares of Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after purchasing an additional 579 shares in the last quarter. Quarry LP purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at $104,000. Finally, New Vernon Capital Holdings II LLC purchased a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at $122,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ CPRX traded up $0.06 during mid-day trading on Thursday, reaching $20.25. The company had a trading volume of 240,071 shares, compared to its average volume of 1,308,659. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of 12.24, a price-to-earnings-growth ratio of 0.81 and a beta of 0.70. The business's 50-day moving average is $21.11 and its 200-day moving average is $22.55. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.00 and a 52 week high of $26.58.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CPRX. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Finally, Wall Street Zen downgraded Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of "Buy" and a consensus target price of $33.20.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 2,324 shares of the stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total transaction of $61,376.84. Following the completion of the sale, the insider directly owned 42,681 shares of the company's stock, valued at approximately $1,127,205.21. This represents a 5.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.